Hybrigenics’ compound inhibits Ubiqitin-Specific Protease 10 (USP10) and shows activity in preclinical models of Acute Myeloid Leukemia (AML)

To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.